^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Hairy Cell Leukemia |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Treatment with an alternate purine analog ± rituximab, interferon alpha, rituximab monotherapy (if unable to receive purine analog) vemurafenib are included as options for patients with disease relapse within 2 years after achieving CR to initial therapy.
Secondary therapy:
cladribine
